NOVATO, Calif., July 13, 2026 /PRNewswire/ — Lighthouse Pharmaceuticals today announced new analyses from the Phase 2/3 GAIN trial demonstrating that atuzaginstat, a gingipain inhibitor targeting Porphyromonas gingivalis (Pg), was associated with benefits in several neuropsychiatric…
Source: prnewswire
Country: United States